

### Claims

1. Sustained release tablet containing indapamide, characterized in that the tablet contains indapamide in the amount 1.5 to 2.5 % of the total mass of the tablet, lactose monohydrate in the amount 30 to 80 % of the total mass of the tablet, copovidon in the amount of 2 to 10 % of the total mass of the tablet, hypromellose in the amount of 20 to 65 % of the total mass of the tablet and lubricants in the amount of 0.1 to 5 % of the total mass of the tablet.
2. Tablet according to claim 1, characterized in that as the lubricants it contains magnesium stearate or/and anhydrous colloidal silica.
3. Tablet according to claim 1, characterized in that hypromellose viscosity is from 1.000 to 20.000 cP.
4. Process of manufacturing sustained release tablet containing indapamide, characterized in that indapamide is mixed with lactose monohydrate and copovidone and then the mixture is moisturised by purified water and its granulation is performed after which the granulate is dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine.